Combination of immunosuppressive drugs leaves specific "fingerprint" on gene expression in vitro. 2009

Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
Renal Division, Department of Internal Medicine, University Hospital, Freiburg, Germany. brigitta.rumberger@krupp-krankenhaus.de

Following organ transplantation many patients suffer from drug-related side effects, or receive more immunosuppression than necessary to prevent rejection. Hence, parameters are needed to tailor the immunosuppressive therapy to the individual needs of an organ recipient. The aim of this study was to determine whether drug combinations provoke specific gene expression patterns in a simple assay system in vitro. Stimulated peripheral blood lymphocytes were cultured in the presence of cyclosporine A, tacrolimus, mycophenolic acid, everolimus and sirolimus, or combinations thereof. Using a cDNA microarray, we found that all samples clustered in drug-specific groups. Gene expression profiles were almost identical in PBL treated with either cyclosporine A or tacrolimus, and with either sirolimus or everolimus. More than 50 genes were synergistically affected by combinations of calcineurin-inhibitors and TOR-inhibitors and drug-specific regulated genes could be identified for both substance groups. Our data suggest that in vitro gene profiling can be used to describe synergistic effects of immunosuppressive drugs. Furthermore, our approach may help to identify marker genes urgently needed to optimize and individualize immunosuppressive drug regimens after organ transplantation.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068338 Everolimus A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT. Zortress,40-O-(2-hydroxyethyl)-rapamycin,Afinitor,Certican,RAD 001,RAD001,SDZ RAD,SDZ-RAD,001, RAD,RAD, SDZ
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions

Related Publications

Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
February 1988, Transplantation proceedings,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
October 1970, Zeitschrift fur Immunitatsforschung, Allergie und klinische Immunologie,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
June 1969, Nature,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
January 2002, Annals of transplantation,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
November 1993, Annals of the New York Academy of Sciences,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
January 1967, Federation proceedings,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
January 1967, Federation proceedings,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
January 1968, Canadian journal of microbiology,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
May 2022, Journal of clinical medicine,
Brigitta Rumberger, and Clemens Kreutz, and Christian Nickel, and Marinella Klein, and Severine Lagoutte, and Sven Teschner, and Jens Timmer, and Peter Gerke, and Gerd Walz, and Johannes Donauer
April 2008, Molecular pharmacology,
Copied contents to your clipboard!